search
  • Country
    Clear
  • Type
  • Compatibility Level
  • Thematic
  • Jurisdiction
2,624 Data sources

  • CN
  • CH
  • SG
  • EU
  • DZ
  • HK

  • more_vert
  • more_vert
  • The Swissregulon Database contains genome-wide annotations of regulatory sites. The predictions are based on Bayesian probabilistic analysis of a combination of input information including i) Experimentally determined binding sites reported in the literature, ii) Known sequence-specificities of transcription factors, iii) ChIP-chip and ChIP-seq data, iiii) Alignments of orthologous non-coding regions.

    more_vert
  • more_vert
  • more_vert
  • Novartis launched the results website in 2005 becoming one of the first companies to publically post results from Phase 2b-4 interventional trials. The Novartis position evolved over time to include public disclosure of results from Phase 1- 2a interventional trials in patients.

    more_vert
  • more_vert
  • The Han Chinese Genomes Database (PGG.Han 2.0) serves as the central repository of the genomic data of the Han Chinese Genomes Project (Phase II). As is its current version, PGG.Han 2.0 archives genomic data of 137,012 Han Chinese individuals (a.k.a. Han100K). Some computational tools are available, as is an interface for data analysis and results visualization.

    more_vert
  • more_vert
  • more_vert
  • chevron_left
  • 11
  • 12
  • 13
  • 14
  • 15
  • chevron_right
2,624 Data sources
  • more_vert
  • more_vert
  • The Swissregulon Database contains genome-wide annotations of regulatory sites. The predictions are based on Bayesian probabilistic analysis of a combination of input information including i) Experimentally determined binding sites reported in the literature, ii) Known sequence-specificities of transcription factors, iii) ChIP-chip and ChIP-seq data, iiii) Alignments of orthologous non-coding regions.

    more_vert
  • more_vert
  • more_vert
  • Novartis launched the results website in 2005 becoming one of the first companies to publically post results from Phase 2b-4 interventional trials. The Novartis position evolved over time to include public disclosure of results from Phase 1- 2a interventional trials in patients.

    more_vert
  • more_vert
  • The Han Chinese Genomes Database (PGG.Han 2.0) serves as the central repository of the genomic data of the Han Chinese Genomes Project (Phase II). As is its current version, PGG.Han 2.0 archives genomic data of 137,012 Han Chinese individuals (a.k.a. Han100K). Some computational tools are available, as is an interface for data analysis and results visualization.

    more_vert
  • more_vert
  • more_vert
  • chevron_left
  • 11
  • 12
  • 13
  • 14
  • 15
  • chevron_right